Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc. (Delaware)

Grade Last Price % Change Price Change
grade D 0.2945 4.25% 0.01
ATNM closed up 4.25 percent on Friday, May 24, 2019, on 57 percent of normal volume.
7 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ATNM trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
20 DMA Resistance Bearish 4.25%
Bollinger Band Squeeze Range Contraction 4.25%
Down 3 Days in a Row Weakness 4.25%
Down 4 Days in a Row Weakness 4.25%
Fell Below 20 DMA Bearish 2.43%
Bollinger Band Squeeze Range Contraction 2.43%
Down 3 Days in a Row Weakness 2.43%
1,2,3 Retracement Bearish Bearish Swing Setup -0.88%

Older signals for ATNM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Chemistry Biopharmaceutical Cancer Physical Sciences Natural Sciences Immunology Chemical Elements Antibodies Stem Cells Acute Myeloid Leukemia Monoclonal Antibody Transplantation Platform Technology Actinides
Is ATNM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 24 Investors Who Bought Actinium Pharmaceuticals (NYSEMKT:ATNM) Shares Five Years Ago Are Now Down 98%
May 16 Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
May 7 Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer
Apr 22 54 Biggest Movers From Thursday
Apr 18 Mid-Day Market Update: Dow Up Over 100 Points; Actinium Pharmaceuticals Shares Plunge
Apr 18 Actinium prices equity offering; shares down 30% premarket
Apr 18 Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants
Apr 17 Actinium launches equity offering; shares down 13% after hours
Apr 17 Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
Apr 8 Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
See more ATNM news...
Indicators
Indicator Value
52 Week High 0.865
52 Week Low 0.2578
Average Volume 1,486,778
200-Day Moving Average 0.5381
50-Day Moving Average 0.4066
20-Day Moving Average 0.2885
10-Day Moving Average 0.2843
Average True Range 0.0282
ADX 32.74
+DI 14.253
-DI 21.5576
Chandelier Exit (Long, 3 ATRs ) 0.2354
Chandelier Exit (Short, 3 ATRs ) 0.3424
Upper Bollinger Band 0.317
Lower Bollinger Band 0.26
Percent B (%b) 0.61
BandWidth 19.757366
MACD Line -0.0303
MACD Signal Line -0.0405
MACD Histogram 0.0103
Fundamentals Value
Market Cap 23.56 Million
Num Shares 80 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -0.57
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.32
Resistance 3 (R3) 0.32 0.31 0.32
Resistance 2 (R2) 0.31 0.30 0.31 0.32
Resistance 1 (R1) 0.30 0.30 0.31 0.30 0.32
Pivot Point 0.29 0.29 0.29 0.29 0.29
Support 1 (S1) 0.28 0.28 0.29 0.28 0.27
Support 2 (S2) 0.27 0.28 0.27 0.27
Support 3 (S3) 0.26 0.27 0.27
Support 4 (S4) 0.26